Inguinal Hernia
Conditions
Keywords
Inguinal hernia repair, Mesh, Groin pain, Testicular pain
Brief summary
There are in excess of 1 million operations performed annually to repair inguinal hernias, mostly in the male population. Unfortunately, some patients continue to suffer both groin or testicular pain for varying lengths of time postoperatively. This can lead to a severe degradation of the patient's lifestyle, work habits and sexual function. The origin of the pain is felt to be secondary to the inflammatory reaction caused by the mesh. This also involves the spermatic cord and its structures, leading to orchidinia and possibly azospermia.
Detailed description
In this prospective randomized trial, male patients with a primary symptomatic unilateral inguinal hernia will be admitted to the trial. All patients must be over 21 years of age. In order to avoid inguinal nerve entrapment or damage by mesh fixation sutures Covidien Parietene ProGrip mesh will be employed. This mesh does not require fixation. Standard open inguinal hernia repair will take place with nerve preservation, as day surgery cases. In the randomized portion of the study, the mesh will be placed as usual along the posterior wall of the inguinal canal, however the inguinal ligament will be interposed between the mesh and the spermatic cord, thus isolating the cord from intimate contact with the mesh, and a reduction in postoperative inflammatory changes.
Interventions
The spermatic cord is isolated from the mesh employed to repair an inguinal hernia following standard open repair.
Sponsors
Study design
Eligibility
Inclusion criteria
* Clinical diagnosis of a primary unilateral inguinal hernia
Exclusion criteria
* Medically unfit for surgical repair
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of groin or testicular pain lasting longer than 3 months postoperatively. | 1 year postoperatively | All patients will be evaluated using the Carolina's Comfort Scale |
Secondary
| Measure | Time frame |
|---|---|
| Number of patients with adverse events. | 1 year |
Countries
Canada